JP2023538945A5 - - Google Patents
Info
- Publication number
- JP2023538945A5 JP2023538945A5 JP2023513532A JP2023513532A JP2023538945A5 JP 2023538945 A5 JP2023538945 A5 JP 2023538945A5 JP 2023513532 A JP2023513532 A JP 2023513532A JP 2023513532 A JP2023513532 A JP 2023513532A JP 2023538945 A5 JP2023538945 A5 JP 2023538945A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- cdr
- polypeptide chain
- antigen
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020110841 | 2020-08-24 | ||
| CNPCT/CN2020/110841 | 2020-08-24 | ||
| CN2020141398 | 2020-12-30 | ||
| CNPCT/CN2020/141398 | 2020-12-30 | ||
| PCT/CN2021/114088 WO2022042488A1 (en) | 2020-08-24 | 2021-08-23 | Anti-ror1 antibodies and related bispecific binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023538945A JP2023538945A (ja) | 2023-09-12 |
| JP2023538945A5 true JP2023538945A5 (https=) | 2024-08-28 |
| JP7781859B2 JP7781859B2 (ja) | 2025-12-08 |
Family
ID=77946069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513532A Active JP7781859B2 (ja) | 2020-08-24 | 2021-08-23 | 抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240010753A1 (https=) |
| EP (1) | EP4200336A4 (https=) |
| JP (1) | JP7781859B2 (https=) |
| KR (1) | KR20230053602A (https=) |
| CN (2) | CN114085288A (https=) |
| AU (1) | AU2021334677A1 (https=) |
| BR (1) | BR112023002895A2 (https=) |
| CA (1) | CA3190117A1 (https=) |
| IL (1) | IL300760A (https=) |
| MX (1) | MX2023002181A (https=) |
| TW (1) | TWI907489B (https=) |
| WO (1) | WO2022042488A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519251B2 (en) * | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| JP7033328B2 (ja) * | 2016-08-16 | 2022-03-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | 一価の非対称タンデムＦａｂ二重特異性抗体 |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| CN114539411B (zh) * | 2022-04-29 | 2022-11-11 | 山东博安生物技术股份有限公司 | 一种ror1抗体或其抗原结合片段 |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| CN118974090A (zh) * | 2022-04-02 | 2024-11-15 | 山东先声生物制药有限公司 | 抗ror1的抗体及其用途 |
| AU2023306100A1 (en) * | 2022-07-15 | 2025-02-06 | Abl Bio Inc. | Anti-ror1 antibody, bispecific antibody comprising same, and uses thereof |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| TW202434635A (zh) * | 2022-11-03 | 2024-09-01 | 美商翰森生物有限責任公司 | 多特異性抗體及其醫藥用途 |
| AU2024331841A1 (en) * | 2023-08-31 | 2026-03-05 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Antibody targeting receptor tyrosine kinase-like orphan receptor 1 and use thereof |
| WO2025061032A1 (zh) * | 2023-09-18 | 2025-03-27 | 南京蓬勃生物科技有限公司 | 靶向人源ror1和cd3的双特异性抗体 |
| TW202542204A (zh) * | 2023-12-29 | 2025-11-01 | 大陸商上海岸邁生物科技有限公司 | 融合蛋白及其用途 |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9242014B2 (en) * | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| EP3604339B1 (en) * | 2011-01-14 | 2021-03-10 | The Regents Of The University Of California | Therapeutic antibodies against ror-1 protein and methods for use of same |
| EP2789630A1 (en) * | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| US10519251B2 (en) * | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| CA2963696A1 (en) * | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer |
| EP3204415B1 (en) * | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| WO2016094873A2 (en) * | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| WO2016187220A2 (en) * | 2015-05-18 | 2016-11-24 | Five Prime Therapeutics, Inc. | Anti-ror1 antibodies |
| WO2017053469A2 (en) * | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| SG11201803098VA (en) * | 2015-10-30 | 2018-05-30 | Nbe Therapeutics Ag | Anti-ror1 antibodies |
| TW201734049A (zh) * | 2016-01-22 | 2017-10-01 | 健生生物科技公司 | 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法 |
| WO2017142928A1 (en) * | 2016-02-17 | 2017-08-24 | Macrogenics, Inc. | Ror1-binding molecules, and methods of use thereof |
| JP7033328B2 (ja) * | 2016-08-16 | 2022-03-10 | エピムアブ バイオセラピューティクス インコーポレイテッド | 一価の非対称タンデムＦａｂ二重特異性抗体 |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710835D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| SG11202010235QA (en) * | 2018-04-18 | 2020-11-27 | Exelixis Inc | Anti-ror antibody constructs |
| SG11202107976SA (en) * | 2019-01-29 | 2021-08-30 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| CN111286512A (zh) * | 2019-06-05 | 2020-06-16 | 南京艾德免疫治疗研究院有限公司 | 靶向人源化酪氨酸激酶孤儿受体1的嵌合抗原受体及其用途 |
| MX2021014973A (es) * | 2019-06-07 | 2022-04-18 | Adimab Llc | Anticuerpos anti-cd3 de alta afinidad y metodos para su generacion y uso. |
| JP7773466B2 (ja) * | 2019-11-26 | 2025-11-19 | シャンハイ エピムアブ バイオセラピューティクス カンパニー リミテッド | Ｃｄ３およびｂｃｍａに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
-
2021
- 2021-08-23 EP EP21860323.1A patent/EP4200336A4/en active Pending
- 2021-08-23 CN CN202110968072.5A patent/CN114085288A/zh active Pending
- 2021-08-23 MX MX2023002181A patent/MX2023002181A/es unknown
- 2021-08-23 US US18/042,762 patent/US20240010753A1/en active Pending
- 2021-08-23 JP JP2023513532A patent/JP7781859B2/ja active Active
- 2021-08-23 TW TW110131088A patent/TWI907489B/zh active
- 2021-08-23 IL IL300760A patent/IL300760A/en unknown
- 2021-08-23 CA CA3190117A patent/CA3190117A1/en active Pending
- 2021-08-23 CN CN202110969266.7A patent/CN113480656B/zh active Active
- 2021-08-23 KR KR1020237005603A patent/KR20230053602A/ko active Pending
- 2021-08-23 BR BR112023002895A patent/BR112023002895A2/pt unknown
- 2021-08-23 AU AU2021334677A patent/AU2021334677A1/en active Pending
- 2021-08-23 WO PCT/CN2021/114088 patent/WO2022042488A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023538945A5 (https=) | ||
| JP7790754B2 (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| CN112955471B (zh) | Cd3抗体及其药物用途 | |
| JP2024510098A (ja) | 抗ＧＰＲＣ５ＤｘＢＣＭＡｘＣＤ３三重特異性抗体およびその使用 | |
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2021512630A5 (https=) | ||
| JP2022551836A (ja) | Ｂｃｍａを標的とする抗体、二重特異性抗体及びその用途 | |
| JP2018502050A5 (https=) | ||
| CN106831996B (zh) | 具有cd3e和/或her2靶向功能的双特异性抗体及其用途 | |
| JP2021520832A5 (https=) | ||
| JP7728595B2 (ja) | 二重特異性抗体及びその用途 | |
| CN118946592A (zh) | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 | |
| CN111093702A (zh) | 靶细胞依赖性T细胞的接合和活化型不对称异二聚Fc-ScFv融合抗体形式用于癌症治疗 | |
| JP2024542192A (ja) | Ｔｉｇｉｔおよびｐｄ－ｌ１に対する二重特異性抗体、ならびにその医薬組成物およびその使用 | |
| WO2023036215A1 (zh) | 双特异性抗原结合分子及其应用 | |
| JP2026508244A (ja) | 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体 | |
| JP2024543822A5 (https=) | ||
| JP2025525885A (ja) | Ｇｕｃｙ２ｃとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用 | |
| JP2025528835A5 (https=) | ||
| KR20260035361A (ko) | 폴리오바이러스 수용체에 대한 항체 및 이의 용도 | |
| EP4702049A1 (en) | Novel egfr binding proteins | |
| KR20250158060A (ko) | 항-cldn6 및 항-cd3 다중특이적 항체 및 사용 방법 | |
| KR20250156803A (ko) | 항-cd3 다중특이적 항체 및 사용 방법 | |
| TW202413416A (zh) | 特異性結合ｅｇｆｒ和ｃｄ２８的抗原結合分子及其醫藥用途 |